BioNotebook: Emergent/Cangene, Sprout, Agios/Celgene, Sutro, Savient/Crealta
This article was originally published in Scrip
Executive Summary
Emergent buys Cangene for $222m; Sprout appeals FDA rejection; Agios, Celgene extend collaboration; Sutro raises $26m Series D; and Savient liquidates to Crealta.